Replies to post #796653 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

So what should our share price be worth today, PRIOR to an MHRA decision?

I thought I’d look back at the NYAS event the day AFTER the P3 DCVax-L data was revealed (at New York Academy of Sciences) to determine the approximate market cap that day after, and check out what the share price would be today with the market cap Northwest had back on May 11, 2022... so:

AFTER P3 data release
BEFORE Flaskworks (closed manufacturing) purchase
BEFORE MHRA submission and close to a decision, and
BEFORE the Advent merge

On May 10, 2022 (the day of the NYAS presentation), according to the 10Q released that same day, the NWBO outstanding share count was:
984,247,092
https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057822001218/nwbo-20220331x10q.htm

The high of the day share price on May 11, 2022 AFTER the data was presented at the NYAS was:
$0.939

Market Cap on May 11, 2022 at high of day (HOD): $.939 x 984,247,092 shares = $924,208,019

Bear in mind, and to repeat:

• by that time the P3 data had been revealed
• Flaskworks had not been purchased
• the MHRA application had not been submitted
• and Advent had not been rolled into NWBO

Using the HOD Market Cap from 5/11/22 and today’s share count: $924,208,019 / 1,445,375,000
I just thought it might be relevant for some to see that when the Northwest Bio market cap was almost $1B, and with the market cap from the day after data release, and applying today’s approx. outstanding shares, our share price today would be $0.64.

One would think that if Northwest is granted an MHRA approval for DCVax-L, our share price should probably be quite a bit more than it was after just the DCVax-L P3 data presentation.

Minimally...

• MHRA approval would represent an impressive regulator validation, one that makes an eventual FDA, EU and Canadian approval (after application submission of course) more likely.

• If NICE will pay for the treatment, it also represents a cash flow to help significantly lessen the current onerous share dilution.

• An MHRA approval also opens more doors for potential and appealing partnerships.

...surely, those likely above noted prospects should get us to a market cap that’s at least 4 or 5x where we are today (a wimpy $347M)?

So I don't think $1.390B or $1.735B would be unreasonable, with just a coveted MHRA approval, and the above possibilities minimally on the table.
Those market caps would equal an approx. $0.96 to $1.20 share price.

I would love for the market cap and share price to be more... I'm simply suggesting what seems like a reasonable expectation.